JP2008523842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523842A5 JP2008523842A5 JP2007548379A JP2007548379A JP2008523842A5 JP 2008523842 A5 JP2008523842 A5 JP 2008523842A5 JP 2007548379 A JP2007548379 A JP 2007548379A JP 2007548379 A JP2007548379 A JP 2007548379A JP 2008523842 A5 JP2008523842 A5 JP 2008523842A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- residues
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 45
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 38
- 125000000539 amino acid group Chemical group 0.000 claims 30
- 238000007912 intraperitoneal administration Methods 0.000 claims 19
- 238000002360 preparation method Methods 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 238000000034 method Methods 0.000 claims 12
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 12
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 102000004127 Cytokines Human genes 0.000 claims 9
- 108090000695 Cytokines Proteins 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- -1 narcotic Substances 0.000 claims 9
- 210000000056 organ Anatomy 0.000 claims 9
- 235000018102 proteins Nutrition 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 9
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 6
- 229930182837 (R)-adrenaline Natural products 0.000 claims 6
- 102000003951 Erythropoietin Human genes 0.000 claims 6
- 108090000394 Erythropoietin Proteins 0.000 claims 6
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 239000003263 anabolic agent Substances 0.000 claims 6
- 230000000202 analgesic effect Effects 0.000 claims 6
- 230000002682 anti-psoriatic effect Effects 0.000 claims 6
- 239000000935 antidepressant agent Substances 0.000 claims 6
- 229940005513 antidepressants Drugs 0.000 claims 6
- 239000003435 antirheumatic agent Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003246 corticosteroid Substances 0.000 claims 6
- 229960005139 epinephrine Drugs 0.000 claims 6
- 229940105423 erythropoietin Drugs 0.000 claims 6
- 239000000122 growth hormone Substances 0.000 claims 6
- 229940088597 hormone Drugs 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 6
- 230000003053 immunization Effects 0.000 claims 6
- 238000002649 immunization Methods 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims 6
- 239000003018 immunosuppressive agent Substances 0.000 claims 6
- 238000001361 intraarterial administration Methods 0.000 claims 6
- 238000007918 intramuscular administration Methods 0.000 claims 6
- 238000001990 intravenous administration Methods 0.000 claims 6
- 238000007914 intraventricular administration Methods 0.000 claims 6
- 239000003589 local anesthetic agent Substances 0.000 claims 6
- 239000003158 myorelaxant agent Substances 0.000 claims 6
- 230000003533 narcotic effect Effects 0.000 claims 6
- 239000000842 neuromuscular blocking agent Substances 0.000 claims 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 6
- 229940121896 radiopharmaceutical Drugs 0.000 claims 6
- 239000012217 radiopharmaceutical Substances 0.000 claims 6
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 6
- 239000000932 sedative agent Substances 0.000 claims 6
- 150000003431 steroids Chemical class 0.000 claims 6
- 238000007920 subcutaneous administration Methods 0.000 claims 6
- 230000009261 transgenic effect Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 241001260012 Bursa Species 0.000 claims 3
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 102000018997 Growth Hormone Human genes 0.000 claims 3
- 108010051696 Growth Hormone Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 229940070021 anabolic steroids Drugs 0.000 claims 3
- 230000003444 anaesthetic effect Effects 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- 230000001430 anti-depressive effect Effects 0.000 claims 3
- 230000003302 anti-idiotype Effects 0.000 claims 3
- 230000000561 anti-psychotic effect Effects 0.000 claims 3
- 230000003356 anti-rheumatic effect Effects 0.000 claims 3
- 229940124350 antibacterial drug Drugs 0.000 claims 3
- 239000000164 antipsychotic agent Substances 0.000 claims 3
- 229940005529 antipsychotics Drugs 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 229940127225 asthma medication Drugs 0.000 claims 3
- 239000002876 beta blocker Substances 0.000 claims 3
- 229940097320 beta blocking agent Drugs 0.000 claims 3
- 239000002981 blocking agent Substances 0.000 claims 3
- 210000000845 cartilage Anatomy 0.000 claims 3
- 210000001638 cerebellum Anatomy 0.000 claims 3
- 229960001334 corticosteroids Drugs 0.000 claims 3
- 239000000409 cytokine receptor agonist Substances 0.000 claims 3
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000003193 general anesthetic agent Substances 0.000 claims 3
- 229940072221 immunoglobulins Drugs 0.000 claims 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000007919 intrasynovial administration Methods 0.000 claims 3
- 238000007913 intrathecal administration Methods 0.000 claims 3
- 229960005015 local anesthetics Drugs 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 210000000664 rectum Anatomy 0.000 claims 3
- 229940125723 sedative agent Drugs 0.000 claims 3
- 230000001624 sedative effect Effects 0.000 claims 3
- 239000000021 stimulant Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 210000001215 vagina Anatomy 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 229930195712 glutamate Natural products 0.000 claims 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims 1
- 102220625422 E3 ubiquitin-protein ligase RNF187_R98K_mutation Human genes 0.000 claims 1
- 102220481770 Kinesin-like protein KIF20A_R59K_mutation Human genes 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 102220094017 rs876659369 Human genes 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63781904P | 2004-12-21 | 2004-12-21 | |
| PCT/US2005/046063 WO2006069036A2 (en) | 2004-12-21 | 2005-12-20 | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523842A JP2008523842A (ja) | 2008-07-10 |
| JP2008523842A5 true JP2008523842A5 (enExample) | 2009-02-12 |
Family
ID=36602254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548379A Pending JP2008523842A (ja) | 2004-12-21 | 2005-12-20 | 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途 |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US8080247B2 (enExample) |
| EP (1) | EP1836294A4 (enExample) |
| JP (1) | JP2008523842A (enExample) |
| KR (1) | KR20070094927A (enExample) |
| CN (1) | CN101120087A (enExample) |
| AR (1) | AR051805A1 (enExample) |
| AU (1) | AU2005319278A1 (enExample) |
| BR (1) | BRPI0515858A (enExample) |
| CA (1) | CA2591813A1 (enExample) |
| CR (1) | CR9265A (enExample) |
| EA (1) | EA016022B1 (enExample) |
| IL (1) | IL183939A0 (enExample) |
| MY (1) | MY157915A (enExample) |
| NI (1) | NI200700155A (enExample) |
| NO (1) | NO20073778L (enExample) |
| NZ (2) | NZ583153A (enExample) |
| PE (1) | PE20061115A1 (enExample) |
| SG (1) | SG158150A1 (enExample) |
| TW (1) | TWI406943B (enExample) |
| UY (1) | UY29291A1 (enExample) |
| WO (1) | WO2006069036A2 (enExample) |
| ZA (1) | ZA200706036B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706264B1 (en) * | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| EP1839120B1 (en) * | 2004-12-21 | 2013-10-23 | Janssen Biotech, Inc. | Anti-il-12 antibody based vectors, host cells, and methods of production and uses |
| CN103146708A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| JP2009507023A (ja) | 2005-09-01 | 2009-02-19 | シェーリング コーポレイション | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
| ES2553553T3 (es) * | 2006-10-02 | 2015-12-10 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
| SG176427A1 (en) | 2006-10-27 | 2011-12-29 | Abbott Biotech Ltd | Crystalline anti-htnfalpha antibodies |
| RU2475265C2 (ru) | 2007-01-16 | 2013-02-20 | Эбботт Лэборетриз | Способы лечения псориаза |
| NZ580379A (en) | 2007-03-29 | 2012-10-26 | Abbott Lab | Crystalline anti-human il-12 antibodies |
| RU2010107994A (ru) | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
| US20090181027A1 (en) * | 2007-09-28 | 2009-07-16 | Paul Dal Monte | Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses |
| US8975382B2 (en) | 2007-11-27 | 2015-03-10 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| AU2009225797A1 (en) | 2008-03-18 | 2009-09-24 | Abbvie Inc. | Methods for treating psoriasis |
| EP2326668B1 (en) | 2008-08-14 | 2018-01-17 | Teva Pharmaceuticals Australia Pty Ltd | Anti-il-12/il-23 antibodies |
| EP2477654A4 (en) * | 2009-09-14 | 2013-01-23 | Abbott Lab | METHOD FOR THE TREATMENT OF DANDRUFFS |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| MX2013007904A (es) * | 2011-01-07 | 2013-08-29 | Abbvie Inc | Anticuerpos anti-il-12/il-23 y usos de los mismos. |
| CN105572380A (zh) * | 2014-11-06 | 2016-05-11 | 上海市东方医院 | Il-12在诊断和治疗非小细胞肺癌远处转移中的应用 |
| JP6871876B2 (ja) * | 2015-03-11 | 2021-05-19 | ラッシュ ユニヴァーシティ メディカル センター | がんを治療するための組成物と方法 |
| MX378572B (es) | 2016-01-22 | 2025-03-11 | Merck Sharp & Dohme Llc | Anticuerpos anti-factor de la coagulacion xi. |
| GEP20227382B (en) | 2016-06-14 | 2022-05-25 | Merck Sharp & Dohme | Anti-coagulation factor xi antibodies |
| KR102318480B1 (ko) * | 2016-08-25 | 2021-10-28 | 제이씨알 파마 가부시키가이샤 | 항체 융합 단백질의 제조 방법 |
| CA3039316A1 (en) | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| CN109813897A (zh) * | 2017-11-18 | 2019-05-28 | 镇江亿特生物科技发展有限公司 | 盐酸可乐定快速时间分辨荧光免疫层析定量检测试纸条 |
| TW202348632A (zh) | 2017-11-28 | 2023-12-16 | 日商中外製藥股份有限公司 | 含有抗原結合域及運輸部分之多胜肽 |
| EP3719036A4 (en) | 2017-11-28 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | LIGANDBINDING MOLECULE WITH ADJUSTABLE LIGANDBINDING ACTIVITY |
| EP3793521A4 (en) | 2018-05-18 | 2022-02-23 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY |
| US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
| US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| CN111549834B (zh) * | 2020-05-17 | 2021-08-10 | 福建金鼎建筑发展有限公司 | 一种基于地表水渗透的基坑开挖模型试验装置及使用方法 |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CN114468015B (zh) * | 2022-03-15 | 2023-10-17 | 重庆大学 | 一种高肉粘性的胶原肠衣及其制备方法和用途 |
| EP4649088A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| CA2441636A1 (en) | 1988-11-10 | 1990-05-10 | The Wistar Institute Of Anatomy And Biology | Natural killer stimulatory factor |
| US5811523A (en) * | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
| US6683046B1 (en) * | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
| DE69034249T2 (de) | 1989-12-22 | 2008-05-29 | F. Hoffmann-La Roche Ag | Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor |
| DE4315127A1 (de) * | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
| ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| KR100358271B1 (ko) | 1994-04-22 | 2003-03-15 | 코릭사 코포레이션 | 보호성면역반응및il-12생산의자극과증강을위한화합물및방법 |
| US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| AU6150498A (en) * | 1997-02-07 | 1998-08-26 | Wistar Institute, The | Methods and compositions for the inhibition of interleukin-12 production |
| US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| ES2386262T3 (es) * | 1998-01-23 | 2012-08-14 | F. Hoffmann-La Roche Ag | Anticuerpos contra IL-12 humana |
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| TR200603997T1 (tr) | 1999-03-25 | 2010-01-21 | Abbott Gmbh & Co. Kg | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
| AU7127600A (en) | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US20030157105A1 (en) * | 2001-05-30 | 2003-08-21 | Carton Jill M. | Anti-p40 immunglobulin derived proteins, compositions, methods and uses |
| KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
-
2005
- 2005-12-20 EA EA200701363A patent/EA016022B1/ru unknown
- 2005-12-20 SG SG200908473-2A patent/SG158150A1/en unknown
- 2005-12-20 JP JP2007548379A patent/JP2008523842A/ja active Pending
- 2005-12-20 AR ARP050105380A patent/AR051805A1/es unknown
- 2005-12-20 NZ NZ583153A patent/NZ583153A/en unknown
- 2005-12-20 KR KR1020077016698A patent/KR20070094927A/ko not_active Ceased
- 2005-12-20 BR BRPI0515858-3A patent/BRPI0515858A/pt not_active Application Discontinuation
- 2005-12-20 NZ NZ555658A patent/NZ555658A/en unknown
- 2005-12-20 WO PCT/US2005/046063 patent/WO2006069036A2/en not_active Ceased
- 2005-12-20 EP EP05854726A patent/EP1836294A4/en not_active Withdrawn
- 2005-12-20 TW TW094145355A patent/TWI406943B/zh active
- 2005-12-20 US US11/722,312 patent/US8080247B2/en not_active Expired - Lifetime
- 2005-12-20 AU AU2005319278A patent/AU2005319278A1/en not_active Abandoned
- 2005-12-20 CN CNA2005800482713A patent/CN101120087A/zh active Pending
- 2005-12-20 CA CA002591813A patent/CA2591813A1/en not_active Abandoned
- 2005-12-20 MY MYPI20056053A patent/MY157915A/en unknown
- 2005-12-21 UY UY29291A patent/UY29291A1/es not_active Application Discontinuation
-
2006
- 2006-01-03 PE PE2006000036A patent/PE20061115A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183939A patent/IL183939A0/en unknown
- 2007-06-15 NI NI200700155A patent/NI200700155A/es unknown
- 2007-07-19 NO NO20073778A patent/NO20073778L/no not_active Application Discontinuation
- 2007-07-20 ZA ZA200706036A patent/ZA200706036B/xx unknown
- 2007-07-20 CR CR9265A patent/CR9265A/es not_active Application Discontinuation
-
2011
- 2011-11-18 US US13/299,831 patent/US8329170B2/en not_active Expired - Lifetime
-
2012
- 2012-11-06 US US13/669,894 patent/US8894990B2/en not_active Expired - Lifetime
-
2014
- 2014-10-13 US US14/512,757 patent/US9428579B2/en not_active Expired - Lifetime
-
2016
- 2016-07-22 US US15/217,099 patent/US9605067B2/en not_active Expired - Lifetime
-
2017
- 2017-02-14 US US15/432,636 patent/US9862766B2/en not_active Expired - Fee Related
- 2017-12-04 US US15/830,586 patent/US20180079809A1/en not_active Abandoned
-
2018
- 2018-12-04 US US16/209,326 patent/US20190085069A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008523842A5 (enExample) | ||
| RU2650767C2 (ru) | Интерлейкин-13-связывающие белки | |
| CA2418962A1 (en) | Anti-dual integrin antibodies, compositions, methods and uses | |
| CA2419205A1 (en) | Anti-tnf antibodies, compositions, methods and uses | |
| JP2023162316A (ja) | 抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置 | |
| JP2016029027A (ja) | プロスタグランジンｅ２結合タンパク質およびこの使用 | |
| JP2004536786A (ja) | インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法 | |
| KR20240170590A (ko) | 항-il23 특이적 항체로 건선성 관절염을 치료하는 안전하고 유효한 방법 | |
| KR20240065333A (ko) | 항-il23 특이적 항체로 건선을 치료하는 방법 | |
| WO2022190034A1 (en) | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody | |
| CA2609349A1 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
| CN114025796A (zh) | 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法 | |
| US20240002494A1 (en) | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | |
| KR20240103043A (ko) | 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법 | |
| WO2022013745A1 (en) | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody | |
| KR20230006551A (ko) | 항-il23 특이적 항체로 크론병을 치료하는 방법 | |
| KR20250111179A (ko) | 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법 | |
| KR20240099352A (ko) | 항-il23 특이적 항체로 크론병을 치료하는 방법 | |
| CN119768427A (zh) | 用于评估il23抗体以及用il23抗体治疗银屑病关节炎的方法 | |
| AU2022233792A9 (en) | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody | |
| JP2026031932A (ja) | 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法 | |
| JP2025157225A (ja) | 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法 | |
| CA3258517A1 (en) | TREATMENT METHOD FOR MILD TO MODERATE PSORIASIS WITH A SPECIFIC IL-23 ANTIBODY | |
| HK1128495B (en) | Interleukin -13 binding proteins | |
| HK1128495A (en) | Interleukin -13 binding proteins |